Project Grant R43TR006093
Award Date 7/1/26
Completion Date 6/30/27
Dollars Obligated $350K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19146, USA
Similar Awards
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award for $275,000 will support the development of a plasmonic nanopore sensor device for quality control of adeno-associated viruses (AAVs) used in gene therapy. The proposed device will enable accurate characterization of AAV payload (single-stranded DNA, double-stranded DNA, or empty) at low, pre-scale-up concentrations to optimize formulations. The project aims to demonstrate the...
- Federal Project Grant Award Summary Capienda Biotech, LLC received a $329,272 Project Grant from the National Center for Advancing Translational Sciences (NCATS) under the NCATS program (CFDA 93.350), awarded August 1, 2025, with completion targeted for January 31, 2027. The company is developing a high-throughput kinetic system instrument that enables rapid characterization of small-molecule drug binding kinetics at unprecedented scale. Building on Phase I National Science Foundation (NSF)...
- Project Grant Summary Precision Quantomics, Inc. received a $570,888 Project Grant from the National Center for Advancing Translational Sciences (NCATS) under the NCATS program (CFDA 93.350), awarded on August 15, 2025, with a completion date of August 14, 2026. The project focuses on developing recombinant human enzyme panels that represent genetic variants in drug-metabolizing enzymes relevant to diverse U.S. patient populations. The deliverable addresses a critical gap in current drug...
- Federal Project Grant Award Summary Onca Bio, Inc. received a $697,696 Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350, effective September 15, 2025, through September 14, 2027. The award funds development of segmented in vitro translation (SIVT) technology to enhance mRNA display-based peptide library diversity for drug discovery applications. The project addresses a key limitation in current macrocyclic peptide synthesis, wherein...
- Federal Grant Award Summary The Ohio State University received a $374,199 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded on July 7, 2025, with completion anticipated by June 30, 2027. The grant supports development of an in situ capsid protein and deoxyribonucleic acid (DNA) imaging platform designed to characterize and quantify therapeutic adeno-associated virus (AAV) titers with enhanced precision and accuracy. The research addresses...
- Federal Grant Award Summary Neucore Bio, Inc. received a $350,000 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded on August 15, 2025, with a completion date of August 14, 2026. The award funds development of the Fibroblast-Derived Engineered Extracellular Vesicle (FiEEV) platform technology for RNA therapeutic delivery to treat Charcot-Marie-Tooth Disease Type 1A (CMT1A), a rare genetic neuromuscular disorder affecting approximately 1 in...
- Federal Project Grant Award Summary The National Science Foundation's Directorate for Technology, Innovation, and Partnerships (TIP) awarded $305,000 to a small business under the SBIR Phase I program (CFDA 47.084) to develop a novel gene therapy platform that overcomes the cargo size limitations of adeno-associated virus (AAV) delivery systems. The project, initiated July 1, 2026 with completion targeted for December 31, 2027, focuses on designing and validating a scalable platform to deliver...
- Federal Project Grant Award Summary Engage Biologics Inc. received a $1.73 million Project Grant from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, under CFDA 93.350, awarded August 1, 2025, with completion targeted for July 31, 2027. The award funds development and validation of the Tethosome platform, a non-viral gene delivery technology designed to enable durable therapeutic transgene expression in target cells. The Tethosome system...
- The National Center for Advancing Translational Sciences (NCATS) awarded a $275,000 Project Grant (CFDA 93.350) to Nectagen Inc. to develop bioprocess-compatible, second-generation nanoclamp affinity resins for the efficient purification of plasma-based therapeutic proteins. The goal is to identify panels of nanoclamps to 5 industrially relevant plasma-based therapeutics, select lead candidates, and optimize the resins for maximum recovery and purity from plasma samples. This project aims to...
- Federal Grant Award Summary Millennial Materials & Devices Inc. received a $306,872 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded on August 1, 2025, with a completion date of July 31, 2026. The company is developing a 3D printed integrated sample preparation and chromatography platform designed to process limited-volume complex biological samples for proteomics research. The platform utilizes custom 3D printable carbon microbead...